TECNOTREE
4.8.2022 11:23:07 CEST | Business Wire | Press release
On Thursday, August 4, 2022, Tecnotree announced its financial results for the second quarter ended June 30, 2022. Tecnotree, the global Digital Business Support Systems (BSS) provider, reported a revenue of EUR 18.3 million in the second quarter, continuing its financial strength with considerable growth in MEA & APAC segments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220804005494/en/
Consolidated highlights of the results of Q2 and Half Year 2022:
- Net sales of EUR 18.3 million in the second quarter, showing 9% growth as compared to last year, and EUR 31.6 million for H1 with 13% growth from last year
- Operating result of EUR 5.1 million in the second quarter, and EUR 7.1 million for H1
- Earnings per share of EUR 0.01 in the second quarter, and EUR 0.02 for H1
- Order book at the end of the period EUR 72.8 million, with 32.4% growth as compared to last year
Tecnotree CEO Padma Ravichander said, “Our customers have responded to our digital stack offering, with a strong order book for which we need to invest to deliver expeditiously. Despite rising costs due to external factors leading to thinner first-half net result margins, we continue to deliver new deployments to Tier-1 clients, which requires a greater initial investment. This investment today will ensure long-term recurring revenue over the next 3-5 years with our new customers by bringing stability. Our Digital Stack 5.0 is richer and capable of serving multiple markets and customers simultaneously.”
Other achievements for the second quarter:
- Achieving the highest order book position of EUR 72.8 million - 32% higher than H1 in 2021, due to a surge in demand for Tecnotree products and solutions in the first half of 2022, with continued support from large tier 1 telecom groups such as MTN, STC, Zain, Ooredoo
- Tecnotree digital BSS suite 5 went live for enterprise and consumer businesses for MTN Uganda, driving process agility and customer delight
- Launch of digital transformation suite for MTN Ghana to meet enterprise market demand and deliver augmented customer experiences
- Tecnotree Awarded as 'Change-maker of the year' by the Helsinki Stock Exchange Foundation, for being instrumental in driving growth in emerging markets with its 5G-ready digital products and solutions
- Launch of 5G cloud-native Digital Provisioning Platform for Zain South Sudan, and another tier 1 operator in the Middle East. Tecnotree DSPS is a pre-integrated suite that enables a centralized system for all provisioning-related planning and task management
- Tecnotree wins ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ for enabling customers to transition to new technologies and digital ecosystems
- Launch of DOCS, a 5G Digital Convergent Charging Platform which supports existing and futuristic monetization requirements of CSPs across the verticals and industries
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) provider, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com or social media channels – LinkedIn I Facebook I Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005494/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom